SCHEMBL6175302

SCHEMBL6175302

CC(c1ccnc(NC(=O)c2cccc(Cl)c2)c1)C1NC(=O)N(c2ccc(OC(F)(F)F)cc2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.45
LIPE Q05469 1/20 0.42
NTRK1 P04629 1/20 0.40
CBLB Q13191 2/20 0.40
SLC5A1 P13866 4/20 0.38
ABL1 P00519 2/20 0.38
MAPKAPK2 P49137 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.37
BRAF P15056 1/20 0.37
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6174274 0.92 GCGR (0.42) LIPECBLBSLC5A1ABL1
SCHEMBL6175133 0.87 GRM5 (0.43) GRM5CBLBBRAFMAPK13MAPK12
SCHEMBL6177007 0.87 TDP1 (0.42) LIPECBLBSLC5A1
SCHEMBL6177220 0.84 LMNA (0.40) LIPESLC5A1
SCHEMBL6174788 0.83 LMNA (0.38) LIPESLC5A1ABL1
SCHEMBL6173626 0.83 SLC5A1 (0.37) NTRK1CBLBSLC5A1ABL1BRAF
SCHEMBL6171770 0.83 LMNA (0.43) CBLBSLC5A1
SCHEMBL6173730 0.83 IDH1 (0.42) BRAF
SCHEMBL6175153 0.83 LIPE (0.43) GRM5LIPENTRK1ABL1BRAF
SCHEMBL6172737 0.82 MAPK1 (0.37) NTRK1CBLBSLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed